Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013

Wed Feb 6, 2013 5:32pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130206:nPnLA55978


SAN DIEGO,  Feb. 6, 2013  /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:
CADX), a biopharmaceutical company focused on acquiring, in-licensing,
developing and commercializing proprietary products principally for use in the
hospital setting, announced today that the company's President and CEO  Ted
Schroeder  will present the company's corporate overview on  Wednesday, February
13, 2013  at  3:30pm Eastern Time  (12:30pm Pacific Time) during the Leerink
Swann Global Healthcare Conference at the Waldorf Astoria Hotel in  New York
City.

The presentation will be simultaneously webcast and can be accessed on Cadence
Pharmaceuticals' website at  www.cadencepharm.com  in the Investors section. A
replay of the webcast will be available approximately three hours following the
live webcast and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting.  The current version of Cadence
Pharmaceuticals' corporate overview may be viewed on the Investors page of 
www.cadencepharm.com  under "Events and Presentations" by selecting "Corporate
Overview."

 Contacts:  William R. LaRue                                  
            
SVP, CFO                                         
            
Cadence Pharmaceuticals, Inc.                    
            
858-436-1400                                     


SOURCE  Cadence Pharmaceuticals, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.